Keybanc analyst Matthew Mishan downgrades Inogen (NASDAQ:INGN) from Overweight to Sector Weight.
PureTech Health Plc Provides Update On Progress Made Across Its Wholly Owned Programs And Founded Entities In 2022
Rapid advancement of PureTech's Wholly Owned Pipeline, with three clinical trials now underway and five completed this year that demonstrated compelling safety and tolerability data for LYT-100 (deupirfenidone) and proof of principle, oral bioavailability and tolerability for LYT-300 (oral allopregnanolone).
